In this first single-cell RNA-seq study of tetramer-sorted T cells from untreated celiac disease patients blood, investigators found that gluten-specific T cells showed distinct transcriptomic profiles consistent with activated effector memory T cells that shared features with Th1 and follicular helper T cells.
Beyond Celiac announced the granting of a two-year established investigator grant award to the University of Sheffield, United Kingdom. The $209,000 investment from Beyond Celiac will make it possible for scientists to expand investigation of the neurological and neuropsychological manifestations of celiac disease and gluten-related disorders.
Synthetic Biologics, Inc., a clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal diseases, announced that patient dosing and observation has been completed in its Phase I clinical trial of SYN-020 intestinal alkaline phosphatase.
Anokion SA announced that the company has initiated patient dosing in the multiple ascending dose portion of its Assessment of KAN-101 in Celiac Disease disease, a Phase I clinical trial evaluating KAN-101 for the treatment of individuals with celiac disease.
Scientists obtained γδ and αβ TCR sequences of >2500 single cells from blood and gut of 5 patients, before and during challenge. We observed extensive sharing between blood and gut γδ and CD8+ αβ T-cell clonotypes even prior to gluten challenge.